305 related articles for article (PubMed ID: 34807232)
1. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.
Li C; Phoon YP; Karlinsey K; Tian YF; Thapaliya S; Thongkum A; Qu L; Matz AJ; Cameron M; Cameron C; Menoret A; Funchain P; Song JM; Diaz-Montero CM; Tamilselvan B; Golden JB; Cartwright M; Rodriguez A; Bonin C; Vella A; Zhou B; Gastman BR
J Exp Med; 2022 Jan; 219(1):. PubMed ID: 34807232
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.
Yan M; Hu J; Ping Y; Xu L; Liao G; Jiang Z; Pang B; Sun S; Zhang Y; Xiao Y; Li X
Front Immunol; 2021; 12():758288. PubMed ID: 34804045
[TBL] [Abstract][Full Text] [Related]
3. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
6. Interferon-Gamma-Producing CD8
Sasson SC; Slevin SM; Cheung VTF; Nassiri I; Olsson-Brown A; Fryer E; Ferreira RC; Trzupek D; Gupta T; Al-Hillawi L; Issaias ML; Easton A; Campo L; FitzPatrick MEB; Adams J; Chitnis M; Protheroe A; Tuthill M; Coupe N; Simmons A; Payne M; Middleton MR; Travis SPL; ; Fairfax BP; Klenerman P; Brain O
Gastroenterology; 2021 Oct; 161(4):1229-1244.e9. PubMed ID: 34147519
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S; Voillet V; Vignard V; Wu Z; Dabrowski C; Jouand N; Beauvais T; Khammari A; Braudeau C; Josien R; Adotevi O; Laheurte C; Aubin F; Nardin C; Rulli S; Gottardo R; Ramchurren N; Cheever M; Fling SP; Church CD; Nghiem P; Dreno B; Riddell SR; Labarriere N
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188038
[TBL] [Abstract][Full Text] [Related]
8. Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.
Krebs FK; Trzeciak ER; Zimmer S; Özistanbullu D; Mitzel-Rink H; Meissner M; Grabbe S; Loquai C; Tuettenberg A
Cancer Med; 2021 Mar; 10(5):1562-1575. PubMed ID: 33449393
[TBL] [Abstract][Full Text] [Related]
9. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
11. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Abbas HA; Hao D; Tomczak K; Barrodia P; Im JS; Reville PK; Alaniz Z; Wang W; Wang R; Wang F; Al-Atrash G; Takahashi K; Ning J; Ding M; Beird HC; Mathews JT; Little L; Zhang J; Basu S; Konopleva M; Marques-Piubelli ML; Solis LM; Parra ER; Lu W; Tamegnon A; Garcia-Manero G; Green MR; Sharma P; Allison JP; Kornblau SM; Rai K; Wang L; Daver N; Futreal A
Nat Commun; 2021 Oct; 12(1):6071. PubMed ID: 34663807
[TBL] [Abstract][Full Text] [Related]
12. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
13. IL-9 promotes the survival and function of human melanoma-infiltrating CD4(+) CD8(+) double-positive T cells.
Parrot T; Allard M; Oger R; Benlalam H; Raingeard de la Blétière D; Coutolleau A; Preisser L; Desfrançois J; Khammari A; Dréno B; Labarrière N; Delneste Y; Guardiola P; Gervois N
Eur J Immunol; 2016 Jul; 46(7):1770-82. PubMed ID: 27094152
[TBL] [Abstract][Full Text] [Related]
14. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
15. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
16. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.
Wu RC; Liu S; Chacon JA; Wu S; Li Y; Sukhumalchandra P; Murray JL; Molldrem JJ; Hwu P; Pircher H; Lizée G; Radvanyi LG
Clin Cancer Res; 2012 May; 18(9):2465-77. PubMed ID: 22307139
[TBL] [Abstract][Full Text] [Related]
17. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
18. CD103
Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
[No Abstract] [Full Text] [Related]
19. Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy.
Attrill GH; Owen CN; Ahmed T; Vergara IA; Colebatch AJ; Conway JW; Nahar KJ; Thompson JF; Pires da Silva I; Carlino MS; Menzies AM; Lo S; Palendira U; Scolyer RA; Long GV; Wilmott JS
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688560
[TBL] [Abstract][Full Text] [Related]
20. A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
Mitra A; Thompson B; Strange A; Amato CM; Vassallo M; Dolgalev I; Hester-McCullough J; Muramatsu T; Kimono D; Puranik AS; Weber JS; Woods D
Clin Cancer Res; 2023 Oct; 29(20):4242-4255. PubMed ID: 37505479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]